Large scale production of recombinant human lactoferrin in the milk of transgenic cows
Related Experiment Video
Updated: Oct 1, 2026

Site-Specific Lysine Lactylation via Genetic Code Expansion in E. coli and Mammalian Cells
Published on: February 24, 2026
Patrick H C van Berkel1, Mick M Welling, Marlieke Geerts
1Pharming, Leiden, The Netherlands. p.berkel@pharming.com
Abstract:
The limited capacity of current bioreactors has led the biopharmaceutical industry to investigate alternative protein expression systems. The milk of transgenic cattle may provide an attractive vehicle for large-scale production of biopharmaceuticals, but there have been no reports on the characteristics of such recombinant proteins. Here we describe the production of recombinant human lactoferrin (rhLF), an iron-binding glycoprotein involved in innate host defense, at gram per liter concentrations in bovine milk. Natural hLF from human milk and rhLF had identical iron-binding and -release properties. Although natural hLF and rhLF underwent differential N-linked glycosylation, they were equally effective in three different in vivo infection models employing immunocompetent and leukocytopenic mice, and showed similar localization at sites of infection. Taken together, the results illustrate the potential of transgenic cattle in the large-scale production of biopharmaceuticals.
Related Concept Videos
Production of Pharmaceuticals
Recombinant DNA Technology
Transgenic Organisms
Upstream Processing
Production of Organic Acids
Cloning of Dolly the Sheep

